Marjan Rouzbahman

Marjan Rouzbahman

Auto-generated profile, based on publicly available information

Marjan Rouzbahman

University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2009 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
PSPatricia A Shaw
Patricia A Shaw
MRMarjan Rouzbahman
Marjan Rouzbahman
EPEllen S Pizer
Ellen S Pizer
MPMelania Pintilie
Melania Pintilie
HBHeather Begley
Heather Begley

1 October 2012 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
CLCheng-Han Lee
Cheng-Han Lee
RARola Ali
Rola Ali
MRMarjan Rouzbahman
Marjan Rouzbahman
AMAdrian Marino-Enriquez
Adrian Marino-Enriquez
MZMeijun Zhu
Meijun Zhu
MNMarisa R. Nucci
Marisa R. Nucci
Endometrial stromal sarcoma (ESS) characterized by YWHAE-FAM22 genetic fusion is histologically higher grade and clinically more aggressive than ESS with JAZF1-SUZ12 or equivalent genetic rearrangements, hence it is clinically important to recognize this subset of ESS. To identify diagnostic immunomarkers for this biologically defined ESS subset, we compared gene expression profiles between YWHAE-FAM22ESS and JAZF1-rearranged ESS. These studies showed consistent upregulation of cyclin D1 in YWHAE-FAM22 ESS compared with JAZF1-SUZ12 ESS. Immunohistochemically, the high-grade round cell component of all 12 YWHAE-FAM22 ESS demonstrated diffuse (≥70%) moderate to strong nuclear cyclin D1 staining, and this diffuse positivity was not seen in 34 ESSs with JAZF1 and equivalent genetic rearrangements or in 21 low-grade ESS with no demonstrable genetic rearrangements. In a series of 243 non-ESS pure uterine mesenchymal and mixed epithelial-mesenchymal tumors, only 2 of 8 undifferentiated endometrial sarcomas with nuclear uniformity and 1 of 80 uterine leiomyosarcomas demonstrate diffuse cyclin D1 immunoreactivity. Both cyclin D1-positive undifferentiated endometrial sarcomas showed diffuse strong CD10 staining, which is consistently absent in the high-grade round cell component of YWHAE-FAM22 ESS. The low-grade spindle cell component of YWHAE-FAM22 ESS showed a spatially heterogenous cyclin D1 staining pattern that was weaker and less diffuse overall. Our findings indicate that cyclin D1 is a sensitive and specific diagnostic immunomarker for YWHAE-FAM22 ESS. When evaluating high-grade uterine sarcomas, cyclin D1 can be included in the immunohistochemical panel as an indicator of YWHAE-FAM22 ESS.

1 October 2017 in Laboratory Investigation
Verified
Journal Article
Closed access
JBJennifer A Bennett
Jennifer A Bennett
VNValentina Nardi
Valentina Nardi
MRMarjan Rouzbahman
Marjan Rouzbahman
VMVicente Morales-Oyarvide
Vicente Morales-Oyarvide
GNG Petur Nielsen
G Petur Nielsen
EOEsther Oliva
Esther Oliva

1 September 2013 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
LHLien N. Hoang
Lien N. Hoang
MMMelissa K. BSc McConechy
Melissa K. BSc McConechy
MKMartin Köbel
Martin Köbel
GHGuangming Han
Guangming Han
MRMarjan Rouzbahman
Marjan Rouzbahman
CLCheng-Han Lee
Cheng-Han Lee
Endometrioid, serous, and clear cell carcinomas are the major types of endometrial carcinoma. Histologic distinction between these different tumor types can be difficult in high-grade cases, in which significant interobserver diagnostic disagreement exists. Endometrioid and clear cell carcinomas frequently harbor ARID1A and/or PTEN mutations. Serous carcinoma acquires TP53 mutations/inactivation at onset, with a significant subset harboring an additional mutation in PPP2R1A. This study examines the correlation between tumor histotype and genotype in 36 previously genotyped high-grade endometrial carcinomas. This included 23 endometrioid/clear cell genotype and 13 serous genotype tumors. Eight subspecialty pathologists reviewed representative online slides and rendered diagnoses before and after receiving p53, p16, and estrogen receptor immunostaining results. κ statistics for histotype-genotype concordance were calculated. The average κ values for histotype-genotype concordance was 0.55 (range, 0.30 to 0.67) on the basis of morphologic evaluation alone and it improved to 0.68 (range, 0.54 to 0.81) after immunophenotype consideration (P<0.001). Genotype-incompatible diagnoses were rendered by at least 2 pathologists in 12 of 36 cases (33%) (3 cases by 2/8 pathologists, 2 by 3/8, 2 by 4/8, 3 by 6/8, 1 by 7/8, and 1 case by 8/8 pathologists). Six of the 12 were endometrioid/clear cell genotype tumors, and the other 6 were serous genotype tumors. The histopathologic features associated with histotype-genotype–discordant cases were reviewed, and specific diagnostic recommendations were made to improve concordance. This study found that although the majority of morphologic diagnoses are genotype concordant, genotype-incompatible diagnoses are made in a significant subset of cases. Judicious use and interpretation of p53 immunohistochemistry in selected scenarios can improve histotype-genotype concordance.

16 January 2015 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
RARola Ali
Rola Ali
MRMarjan Rouzbahman
Marjan Rouzbahman
Endometrial stromal tumours (EST) are rare tumours of endometrial stromal origin that account for less than 2% of all uterine tumours. Recent cytogenetic and molecular advances in this area have improved our understanding of ESTs and helped refine their classification into more meaningful categories. Accordingly, the newly released 2014 WHO classification system recognises four categories: endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LGESS), high-grade endometrial stromal sarcoma (HGESS) and undifferentiated uterine sarcoma (UUS). At the molecular level, these tumours may demonstrate a relatively simple karyotype with a defining chromosomal rearrangement (as in the majority of ESNs, LGESSs and YWHAE -rearranged HGESS) or demonstrate complex cytogenetic aberrations lacking specific rearrangements (as in UUSs). Herein we provide an update on this topic aimed at the practicing pathologist.

1 December 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
SGSwati Garg
Swati Garg
TNTeddy S. Nagaria
Teddy S. Nagaria
BCBlaise Clarke
Blaise Clarke
OFOrit Freedman
Orit Freedman
ZKZanobia Khan
Zanobia Khan
MRMarjan Rouzbahman
Marjan Rouzbahman